Table 2 Univariate analysis: overall survival in correlation with clinico-pathological parameters, applied chemotherapy regimens, intrinsic subtypes und subgroups in pre-therapeutic biopsy specimens.
From: Biomarker dynamics and prognosis in breast cancer after neoadjuvant chemotherapy
N (percentage) = 342 (100%) | HR (95%CI) of overall survival | p value | |
|---|---|---|---|
Age (median, range) | 49 (25–81) | 1.02 (CI 1.00–1.05) | 0.015 |
cT stage | |||
cT1 | 55 (16%) | 1.0 | 0.003 |
cT2 | 168 (49%) | 3.52 (CI 0.83–14.98) | |
cT3-4 | 118 (35%) | 6.62 (CI 1.56–27.73) | |
ypT stage | |||
ypT0 | 107 (31.3%) | 1.0 | < 0.001 |
ypT1 | 107 (31.3%) | 1.92 (CI 0.73–5.07) | |
ypT2 | 75 (22%) | 3.32 (CI 1.29–8.49) | |
ypT3-4 | 52 (15.1%) | 6.56 (CI 2.62–16.45) | |
NA | 1 (0.3%) | ||
cN stage | |||
cN0 | 88 (25.7%) | 3.49 (CI 1.39–8.75) | 0.005 |
cN1-3 | 248 (72.5%) | ||
NA | 6 (1.8%) | ||
ypN stage | |||
ypN0 | 176 (51.5%) | 4.65 (CI 2.38–9.12) | < 0.001 |
ypN1-3 | 131 (38.3%) | ||
NA | 35 (10.2%) | ||
cM stage | |||
cM0 | 293 (85.6%) | 5.88 (CI 3.39–10.19) | < 0.001 |
cM1 | 46 (13.5%%) | ||
NA | 3 (0.9%) | ||
Preoperative histological grading | |||
G1/2 | 131 (38.3%) | 1.38 (CI 0.78–2.44) | 0.27 |
G3 | 188 (55.0%) | ||
NA | 23 (6.7%) | ||
Proliferation Index Ki67 | |||
Low (< 30%) | 110 (32.1%) | 3.01 (CI 1.46–6.21) | 0.002 |
High (≥ 30%) | 68 (19.9%) | ||
NA | 164 (48.0%) | ||
Pathologic complete response | |||
No | 239 (70%) | 0.15 (CI 0.05–0.47) | < 0.001 |
Yes | 103 (30%) | ||
Subtype | |||
Luminal A | 75 (21.9%) | 1.0 | < 0.001 |
Luminal B Her2+ | 72 (21.1%) | 0.66 (CI 0.23–1.99) | |
Luminal B Her2− | 44 (12.9%) | 3.79 (CI 1.68–8.51) | |
HER2+ | 60 (17.5%) | 1.02 (CI 0.36–2.86) | |
Triple Negative | 90 (26.3%) | 2.65 (CI 1.19–5.89) | |
NA | 1 (0.3%) | ||
Chemotherapy | |||
HER2-antibody therapy | 94 (27.5%) | 1.0 | 0.043 |
Platinum | 64 (18.7%) | 2.75 (CI 1.06–7.10) | |
Others | 164 (48.0%) | 2.64 (CI 1.17–5.95) | |
Combination of antibody and platinum | 19 (5.5%) | 0.67 (CI 0.08–5.50) | |
NA | 1 (0.3%) | ||
Subgroups | |||
2003–2009 | 80 (23%) | 0.74 (CI 0.42–1.33) | 0.312 |
2010–2017 | 262 (77%) |
